Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13493
- Acceso en línea:
- https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltext
http://hdl.handle.net/20.500.12010/13493
https://doi.org/10.1016/j.eclinm.2020.100459
- Palabra clave:
- tocilizumab
tocilizumab
anti-soluble IL-6 receptor
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido
| id |
UTADEO2_f3a4382a3e9937fbd937fa5ca030d4bb |
|---|---|
| oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13493 |
| network_acronym_str |
UTADEO2 |
| network_name_str |
Expeditio: repositorio UTadeo |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| title |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| spellingShingle |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up tocilizumab tocilizumab anti-soluble IL-6 receptor Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| title_short |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| title_full |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| title_fullStr |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| title_full_unstemmed |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| title_sort |
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up |
| dc.subject.spa.fl_str_mv |
tocilizumab tocilizumab anti-soluble IL-6 receptor |
| topic |
tocilizumab tocilizumab anti-soluble IL-6 receptor Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| dc.subject.lemb.spa.fl_str_mv |
Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| description |
Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19. |
| publishDate |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2020-09-21T13:39:05Z |
| dc.date.available.none.fl_str_mv |
2020-09-21T13:39:05Z |
| dc.date.created.none.fl_str_mv |
2020-08-01 |
| dc.type.local.spa.fl_str_mv |
Artículo |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| format |
http://purl.org/coar/resource_type/c_6501 |
| dc.identifier.issn.spa.fl_str_mv |
2589-5370 |
| dc.identifier.other.spa.fl_str_mv |
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltext |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/13493 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/j.eclinm.2020.100459 |
| identifier_str_mv |
2589-5370 |
| url |
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltext http://hdl.handle.net/20.500.12010/13493 https://doi.org/10.1016/j.eclinm.2020.100459 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
| dc.rights.local.spa.fl_str_mv |
Acceso restringido |
| rights_invalid_str_mv |
Acceso restringido http://purl.org/coar/access_right/c_16ec |
| dc.format.extent.spa.fl_str_mv |
9 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
EClinicalMedicine |
| dc.source.spa.fl_str_mv |
reponame:Expeditio Repositorio Institucional UJTL instname:Universidad de Bogotá Jorge Tadeo Lozano |
| instname_str |
Universidad de Bogotá Jorge Tadeo Lozano |
| institution |
Universidad de Bogotá Jorge Tadeo Lozano |
| reponame_str |
Expeditio Repositorio Institucional UJTL |
| collection |
Expeditio Repositorio Institucional UJTL |
| bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/3/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.pdf https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/4/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.png https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/5/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.pdf.jpg |
| bitstream.checksum.fl_str_mv |
915acd9666b0cacc25fae7e2d47fd31b abceeb1c943c50d3343516f9dbfc110f 8f7f456eef6f12155d9b47d02b1ed59d 307478dff5a228c677280991d601cac0 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
| repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
| _version_ |
1814213570995421184 |
| spelling |
2020-09-21T13:39:05Z2020-09-21T13:39:05Z2020-08-012589-5370https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltexthttp://hdl.handle.net/20.500.12010/13493https://doi.org/10.1016/j.eclinm.2020.1004599 páginasapplication/pdfengEClinicalMedicinereponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo Lozanotocilizumabtocilizumabanti-soluble IL-6 receptorSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusEarly use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-upArtículohttp://purl.org/coar/resource_type/c_6501Acceso restringidohttp://purl.org/coar/access_right/c_16ecPneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19.De Rossi, NicolaScarpazza, CristinaFilippini, ChiaraCordioli, CinziaRasia, SarahMancinelli, Chiara RosaRizzoni, DamianoRomanelli, GiuseppeCossi, StefaniaVettoretto, NereoBove, SergioManfredini, SilvanoBeindorf, Eva AndreaMosca, CarloScipione, VittorioFlamminio, GigliolaAlbini Albini, ElenaGiansiracusa, PaolaCapra, Ruggeroon behalf of Montichiari COVID-19 Study GroupORIGINALEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pdfEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pdfDocumento Reservadoapplication/pdf835976https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/3/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.pdf915acd9666b0cacc25fae7e2d47fd31bMD53embargoed access|||2420-09-21LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pngEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pngimage/png123639https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/4/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.png8f7f456eef6f12155d9b47d02b1ed59dMD54open accessEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pdf.jpgEarly use of low dose tocilizumab in patients with COVID-19 A retrospective cohort study with a complete follow-up.pdf.jpgIM Thumbnailimage/jpeg14576https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13493/5/Early%20use%20of%20low%20dose%20tocilizumab%20in%20patients%20with%20COVID-19%20A%20retrospective%20cohort%20study%20with%20a%20complete%20follow-up.pdf.jpg307478dff5a228c677280991d601cac0MD55open access20.500.12010/13493oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/134932020-09-21 08:43:22.325embargoed access|||2420-09-21Repositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.coQXV0b3Jpem8gYWwgU2lzdGVtYSBkZSBCaWJsaW90ZWNhcyBVbml2ZXJzaWRhZCBkZSBCb2dvdMOhIEpvcmdlIFRhZGVvIExvemFubyBwYXJhIHF1ZSBjb24gZmluZXMgYWNhZMOpbWljb3MsIHByZXNlcnZlLCBjb25zZXJ2ZSwgb3JnYW5pY2UsIGVkaXRlIHkgbW9kaWZpcXVlIHRlY25vbMOzZ2ljYW1lbnRlIGVsIGRvY3VtZW50byBhbnRlcmlvcm1lbnRlIGNhcmdhZG8gYWwgUmVwb3NpdG9yaW8gSW5zdGl0dWNpb25hbCBFeHBlZGl0aW8KCkV4Y2VwdHVhbmRvIHF1ZSBlbCBkb2N1bWVudG8gc2VhIGNvbmZpZGVuY2lhbCwgYXV0b3Jpem8gYSB1c3VhcmlvcyBpbnRlcm5vcyB5IGV4dGVybm9zIGRlIGxhIEluc3RpdHVjacOzbiBhIGNvbnN1bHRhciB5IHJlcHJvZHVjaXIgZWwgY29udGVuaWRvIGRlbCBkb2N1bWVudG8gcGFyYSBmaW5lcyBhY2Fkw6ltaWNvcyBudW5jYSBwYXJhIHVzb3MgY29tZXJjaWFsZXMsIGN1YW5kbyBtZWRpYW50ZSBsYSBjb3JyZXNwb25kaWVudGUgY2l0YSBiaWJsaW9ncsOhZmljYSBzZSBsZSBkZSBjcsOpZGl0byBhIGxhIG9icmEgeSBzdShzKSBhdXRvcihzKS4KCkV4Y2VwdHVhbmRvIHF1ZSBlbCBkb2N1bWVudG8gc2VhIGNvbmZpZGVuY2lhbCwgYXV0b3Jpem8gYXBsaWNhciBsYSBsaWNlbmNpYSBkZWwgZXN0w6FuZGFyIGludGVybmFjaW9uYWwgQ3JlYXRpdmUgQ29tbW9ucyAoQXR0cmlidXRpb24tTm9uQ29tbWVyY2lhbC1Ob0Rlcml2YXRpdmVzIDQuMCBJbnRlcm5hdGlvbmFsKSBxdWUgaW5kaWNhIHF1ZSBjdWFscXVpZXIgcGVyc29uYSBwdWVkZSB1c2FyIGxhIG9icmEgZGFuZG8gY3LDqWRpdG8gYWwgYXV0b3IsIHNpbiBwb2RlciBjb21lcmNpYXIgY29uIGxhIG9icmEgeSBzaW4gZ2VuZXJhciBvYnJhcyBkZXJpdmFkYXMuCgpFbCAobG9zKSBhdXRvcihlcykgY2VydGlmaWNhKG4pIHF1ZSBlbCBkb2N1bWVudG8gbm8gaW5mcmluZ2UgbmkgYXRlbnRhIGNvbnRyYSBkZXJlY2hvcyBpbmR1c3RyaWFsZXMsIHBhdHJpbW9uaWFsZXMsIGludGVsZWN0dWFsZXMsIG1vcmFsZXMgbyBjdWFscXVpZXIgb3RybyBkZSB0ZXJjZXJvcywgYXPDrSBtaXNtbyBkZWNsYXJhbiBxdWUgbGEgVW5pdmVyc2lkYWQgSm9yZ2UgVGFkZW8gTG96YW5vIHNlIGVuY3VlbnRyYSBsaWJyZSBkZSB0b2RhIHJlc3BvbnNhYmlsaWRhZCBjaXZpbCwgYWRtaW5pc3RyYXRpdmEgeS9vIHBlbmFsIHF1ZSBwdWVkYSBkZXJpdmFyc2UgZGUgbGEgcHVibGljYWNpw7NuIGRlbCB0cmFiYWpvIGRlIGdyYWRvIHkvbyB0ZXNpcyBlbiBjYWxpZGFkIGRlIGFjY2VzbyBhYmllcnRvIHBvciBjdWFscXVpZXIgbWVkaW8uCgpFbiBjdW1wbGltaWVudG8gY29uIGxvIGRpc3B1ZXN0byBlbiBsYSBMZXkgMTU4MSBkZSAyMDEyIHkgZXNwZWNpYWxtZW50ZSBlbiB2aXJ0dWQgZGUgbG8gZGlzcHVlc3RvIGVuIGVsIEFydMOtY3VsbyAxMCBkZWwgRGVjcmV0byAxMzc3IGRlIDIwMTMsIGF1dG9yaXpvIGEgbGEgVW5pdmVyc2lkYWQgSm9yZ2UgVGFkZW8gTG96YW5vIGEgcHJvY2VkZXIgY29uIGVsIHRyYXRhbWllbnRvIGRlIGxvcyBkYXRvcyBwZXJzb25hbGVzIHBhcmEgZmluZXMgYWNhZMOpbWljb3MsIGhpc3TDs3JpY29zLCBlc3RhZMOtc3RpY29zIHkgYWRtaW5pc3RyYXRpdm9zIGRlIGxhIEluc3RpdHVjacOzbi4gRGUgY29uZm9ybWlkYWQgY29uIGxvIGVzdGFibGVjaWRvIGVuIGVsIGFydMOtY3VsbyAzMCBkZSBsYSBMZXkgMjMgZGUgMTk4MiB5IGVsIGFydMOtY3VsbyAxMSBkZSBsYSBEZWNpc2nDs24gQW5kaW5hIDM1MSBkZSAxOTkzLCBhY2xhcmFtb3MgcXVlIOKAnExvcyBkZXJlY2hvcyBtb3JhbGVzIHNvYnJlIGVsIHRyYWJham8gc29uIHByb3BpZWRhZCBkZSBsb3MgYXV0b3Jlc+KAnSwgbG9zIGN1YWxlcyBzb24gaXJyZW51bmNpYWJsZXMsIGltcHJlc2NyaXB0aWJsZXMsIGluZW1iYXJnYWJsZXMgZSBpbmFsaWVuYWJsZXMuCgpDb24gZWwgcmVnaXN0cm8gZW4gbGEgcMOhZ2luYSwgYXV0b3Jpem8gZGUgbWFuZXJhIGV4cHJlc2EgYSBsYSBGVU5EQUNJw5NOIFVOSVZFUlNJREFEIERFIEJPR09Uw4EgSk9SR0UgVEFERU8gTE9aQU5PLCBlbCB0cmF0YW1pZW50byBkZSBtaXMgZGF0b3MgcGVyc29uYWxlcyBwYXJhIHByb2Nlc2FyIG8gY29uc2VydmFyLCBjb24gZmluZXMgZXN0YWTDrXN0aWNvcywgZGUgY29udHJvbCBvIHN1cGVydmlzacOzbiwgYXPDrSBjb21vIHBhcmEgZWwgZW52w61vIGRlIGluZm9ybWFjacOzbiB2w61hIGNvcnJlbyBlbGVjdHLDs25pY28sIGRlbnRybyBkZWwgbWFyY28gZXN0YWJsZWNpZG8gcG9yIGxhIExleSAxNTgxIGRlIDIwMTIgeSBzdXMgZGVjcmV0b3MgY29tcGxlbWVudGFyaW9zIHNvYnJlIFRyYXRhbWllbnRvIGRlIERhdG9zIFBlcnNvbmFsZXMuIEVuIGN1YWxxdWllciBjYXNvLCBlbnRpZW5kbyBxdWUgcG9kcsOpIGhhY2VyIHVzbyBkZWwgZGVyZWNobyBhIGNvbm9jZXIsIGFjdHVhbGl6YXIsIHJlY3RpZmljYXIgbyBzdXByaW1pciBsb3MgZGF0b3MgcGVyc29uYWxlcyBtZWRpYW50ZSBlbCBlbnbDrW8gZGUgdW5hIGNvbXVuaWNhY2nDs24gZXNjcml0YSBhbCBjb3JyZW8gZWxlY3Ryw7NuaWNvIHByb3RlY2Npb25kYXRvc0B1dGFkZW8uZWR1LmNvLgoKTGEgRlVOREFDScOTTiBVTklWRVJTSURBRCBERSBCT0dPVMOBIEpPUkdFIFRBREVPIExPWkFOTyBubyB1dGlsaXphcsOhIGxvcyBkYXRvcyBwZXJzb25hbGVzIHBhcmEgZmluZXMgZGlmZXJlbnRlcyBhIGxvcyBhbnVuY2lhZG9zIHkgZGFyw6EgdW4gdXNvIGFkZWN1YWRvIHkgcmVzcG9uc2FibGUgYSBzdXMgZGF0b3MgcGVyc29uYWxlcyBkZSBhY3VlcmRvIGNvbiBsYSBkaXJlY3RyaXogZGUgUHJvdGVjY2nDs24gZGUgRGF0b3MgUGVyc29uYWxlcyBxdWUgcG9kcsOhIGNvbnN1bHRhciBlbjogaHR0cDovL3d3dy51dGFkZW8uZWR1LmNvL2VzL2xpbmsvZGVzY3VicmUtbGEtdW5pdmVyc2lkYWQvMi9kb2N1bWVudG9zCg== |